Trial Outcomes & Findings for Field Usability Study of Eclipse Mask (NCT NCT05559047)

NCT ID: NCT05559047

Last Updated: 2025-11-10

Results Overview

The total count of participants who asked for additional information during the course of home use of the mask was recorded

Recruitment status

COMPLETED

Target enrollment

70 participants

Primary outcome timeframe

Throughout the duration of the study (48 hours)

Results posted on

2025-11-10

Participant Flow

In this study, seventy adherent CPAP users volunteered to trial the Eclipse mask for two nights in their homes. Participants attended an appointment at one of three offices of Sleep Centers of Middle Tennessee (SCMT) and were trained how to use the Eclipse mask, then asked to use the Eclipse for two consecutive nights and then complete a participant survey after the second night. No control group was used. Volunteers were gathered from the pool of SCMT participants.

Participant milestones

Participant milestones
Measure
Eclipse Mask Group (Single Arm Study)
A single group was used, namely those trying the Eclipse mask at home for 2 nights
Overall Study
STARTED
70
Overall Study
COMPLETED
70
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Field Usability Study of Eclipse Mask

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Eclipse Mask (Single Arm Study)
n=70 Participants
Seventy adherent CPAP users will volunteer to trial the Eclipse mask for two nights in their homes. Participants who attend an appointment at one of three offices of Sleep Centers of Middle Tennessee (SCMT) and will be trained on how to use the Eclipse mask, then asked to use the Eclipse for two consecutive nights and then complete a participant survey after the second night. Eclipse novel CPAP mask: Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring). Participants will follow instructions to set up and put on the mask. They will fill out a survey about the ease and comfort of putting on and wearing the mask, briefly.
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
68 Participants
n=5 Participants
Age, Categorical
>=65 years
2 Participants
n=5 Participants
Sex: Female, Male
Female
26 Participants
n=5 Participants
Sex: Female, Male
Male
44 Participants
n=5 Participants
Race/Ethnicity, Customized
White
23 participants
n=5 Participants
Race/Ethnicity, Customized
Black
26 participants
n=5 Participants
Race/Ethnicity, Customized
Hispanic
14 participants
n=5 Participants
Race/Ethnicity, Customized
Asian
7 participants
n=5 Participants

PRIMARY outcome

Timeframe: Throughout the duration of the study (48 hours)

The total count of participants who asked for additional information during the course of home use of the mask was recorded

Outcome measures

Outcome measures
Measure
Eclipse Novel CPAP Mask
n=70 Participants
Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).
Number of Participants Who Asked for Additional Information
6 Participants

PRIMARY outcome

Timeframe: At 48 hours

A 16-item patient survey was administered to the participants at the end of the study. Patients had to answer according to a Likert scale (1: worst, 5:best). Here, this reflects the average of all the answered items. For example, question number one had an average score of 4.52, question number 2 had an average score of 4.21, etc. Since all questions reflect mask likability, they were averaged to provide an overall score.

Outcome measures

Outcome measures
Measure
Eclipse Novel CPAP Mask
n=70 Participants
Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).
Mask Likeability
4.1 score
Standard Deviation 0.4

PRIMARY outcome

Timeframe: The duration of the trial (48 h)

Total count of participants who reported technical issues during the course of the 48 h home use of the mask were recorded

Outcome measures

Outcome measures
Measure
Eclipse Novel CPAP Mask
n=70 Participants
Participants will follow instructions to set up and put on the Eclipse nasal mask. The Eclipse removes the headgear associated with traditional CPAP masks, offering a small compact design weighing less than an ounce. The Eclipse uses small and lightweight adhesive seals around the nostrils to create an ergonomic design which accommodates the shape of each individual user. It completes a perfect circuit for CPAP therapy to deliver pressure to the airway and stabilize the user's disordered breathing during sleep (apnea and snoring).
Number of Participants Who Experienced Technical Issues
7 Participants

Adverse Events

Eclipse Novel CPAP Mask

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Stuart Heatherington

Bleep, LLC

Phone: 919-619-7170

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place